Publication: 2008

A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance)
      QxMD      Google Scholar   
Citation:
Invest New Drugs vol 31 (5) 1311-1320
Year:
2013
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
3
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA047577, U10 CA032291, U10 CA077298, CA33601, CA77597, CA101140, U10 CA077658, CA77406, CA47577, CA35113, U10 CA077406, CA32291, U10 CA086726, U10 CA045564, CA41287, U10 CA008025, U10 CA045808, CA03927, U10 CA031946, U10 CA033601, U10 CA045389, CA59518, U10 CA021060, CA45389, CA37447, U10 CA077597, CA45808, U10 CA059518, CA37347, U10 CA114558, CA12046, U10 CA045418, CA86726, U10 CA077440, CA16450, U10 CA037447, U10 CA101140, CA77440, U10 CA041287, U10 CA016450, CA45564, U10 CA035113, U10 CA047559, CA08025, CA21060, U10 CA012046, CA47559, CA114558-02, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31946, U10 CA003927  
Corr. Author:
 
Authors:
                       
Networks:
 
Study
CALGB-10105
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Angiogenesis inhibitors, humans, myelodysplastic syndromes, treatment outcome, vascular endothelial growth factor